Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-3.49Last Year’s EPS
-7.1Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -8.24%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted the successful launch and significant growth of Rezdiffra, with strong financial performance and upcoming regulatory milestones in Europe. However, there are challenges with increased operational expenses and uncertainties in the European market strategy.Company Guidance
During the first quarter of 2025, Madrigal Pharmaceuticals reported impressive performance metrics for Rezdiffra, the first FDA-approved medicine for MASH. Rezdiffra generated $137 million in net sales, representing a 33% increase quarter-over-quarter, with 17,000 patients actively on therapy, up from 11,800 at the end of 2024. The product achieved over 80% commercial payer coverage and secured a 70% prescription rate among their top 6,000 target prescribers. Rezdiffra's real-world profile demonstrates a 6.7 kPa reduction in liver stiffness in F4c patients, which is associated with a lower risk of progression to end-stage liver disease. As of Q1 2025, Madrigal maintains a strong financial position with $848.1 million in cash and equivalents, supporting continued US launch efforts and anticipated European expansion.Successful US Launch of Rezdiffra
Achieved over 80% commercial payer coverage and treated more than 17,000 patients, generating $317 million in net sales in the first 12 months.
Strong Q1 2025 Financial Performance
Net sales for Q1 2025 were $137 million, up 33% quarter-over-quarter, despite typical Q1 headwinds.
Significant Growth in Patient Adoption
Ended Q1 2025 with more than 17,000 patients on Rezdiffra, up from 11,800 at the end of Q4 2024.
High Physician Penetration Rate
70% of the 6,000 top target prescribers have prescribed Rezdiffra, demonstrating strong healthcare provider engagement.
Compelling Two-Year F4c Data
Patients saw a mean reduction of 6.7 kilopascals in liver stiffness at two years, suggesting many patients are moving into a lower risk category.
Upcoming Regulatory Decision in Europe
On track for a mid-year regulatory decision in Europe with plans to launch in Germany in the second half of the year.
Strong Financial Position
Ended Q1 2025 with $848.1 million in cash, cash equivalents, restricted cash, and marketable securities.
---
MDGL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MDGL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 01, 2025 | $333.91 | $327.70 | -1.86% |
| Feb 26, 2025 | $309.49 | $355.88 | +14.99% |
| Oct 31, 2024 | $215.93 | $259.34 | +20.10% |
| Aug 07, 2024 | $266.56 | $234.08 | -12.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Madrigal Pharmaceuticals Inc (MDGL) report earnings?
Madrigal Pharmaceuticals Inc (MDGL) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Madrigal Pharmaceuticals Inc (MDGL) earnings time?
Madrigal Pharmaceuticals Inc (MDGL) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDGL EPS forecast?
MDGL EPS forecast for the fiscal quarter 2025 (Q2) is -3.49.
---